Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · IEX Real-Time Price · USD
1.650
+0.050 (3.12%)
May 2, 2024, 3:50 PM EDT - Market open
Milestone Pharmaceuticals Revenue
In the year 2023, Milestone Pharmaceuticals had annual revenue of $1.00M, a decrease of -80.00%.
Revenue (ttm)
$1.00M
Revenue Growth
-80.00%
P/S Ratio
87.07
Revenue / Employee
$21,277
Employees
47
Market Cap
87.17M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1.00M | -4.00M | -80.00% |
| Dec 31, 2022 | 5.00M | -10.00M | -66.67% |
| Dec 31, 2021 | 15.00M | - | - |
| Dec 31, 2020 | 0 | - | - |
| Dec 31, 2019 | 0 | - | - |
| Dec 31, 2018 | 0 | - | - |
| Dec 31, 2017 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Spero Therapeutics | 103.78M |
| Protalix BioTherapeutics | 65.49M |
| Forian | 20.48M |
| HOOKIPA Pharma | 20.13M |
| Cue Biopharma | 5.49M |
| Barinthus Biotherapeutics | 802.00K |
| Chimerix | 41.00K |
MIST News
- 15 days ago - Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium - GlobeNewsWire
- 24 days ago - Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting - GlobeNewsWire
- 4 weeks ago - Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences - GlobeNewsWire
- 6 weeks ago - Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update - GlobeNewsWire
- 2 months ago - Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants - GlobeNewsWire
- 2 months ago - Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants - GlobeNewsWire
- 3 months ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Milestone Pharmaceuticals Inc.- MIST - PRNewsWire